GlassScriptPhysician profile
Alan Zweben
NPI 1710047022
$3,741.09
in general payments reported to CMS, 2019-2025
24 companies · $202 in 2025
The $202 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $605 · 2020: $255 · 2021: $636 · 2022: $939 · 2023: $610 · 2024: $493 · 2025: $202.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,305.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,305.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $999.83 | 2019-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $752.31 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $590.06 | 2021-2024 | Vraylar |
| Astrazeneca Pharmaceuticals LP | $230.68 | 2019-2024 | Lokelma |
| Astellas Pharma US INC | $213.13 | 2019-2025 | Veozah |
| Pfizer INC. | $140.68 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $132.88 | 2023-2025 | Jardiance |
| Glaxosmithkline, LLC. | $124.34 | 2020-2024 | Jemperli, Zejula |
| Biohaven Pharmaceutical Holding Company LTD. | $88.21 | 2022 | |
| Sanofi-Aventis U.S. LLC | $69.42 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $68.05 | 2019-2022 | |
| Amarin Pharma, INC. | $62.77 | 2019 | |
| Merck Sharp & Dohme LLC | $59.82 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $37.56 | 2019-2022 | |
| Xeris Pharmaceuticals, INC. | $29.05 | 2023 | Gvoke Hypopen |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $22.51 | 2024 | |
| Eisai INC. | $21.46 | 2024 | |
| Esperion Therapeutics, INC. | $19.74 | 2020 | |
| Allergan, INC. | $18.34 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $14.28 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $14.23 | 2023 | Rexulti |
| Abbott Laboratories | $13.88 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $11.22 | 2020 | |
| Dynavax Technologies Corporation | $6.64 | 2023 | Heplisav-B |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Zweben listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.